On April 23, 2026, Acting Attorney General Todd Blanche signed a final order placing state-licensed medical marijuana and FDA-approved drug products containing marijuana into Schedule III of the Controlled Substances Act. The order took effect April 28, 2026. For DOs operating in the two-hat model — VA Community Care under one hat, state-legal medical cannabis evaluations under the other — the rescheduling creates new federal compliance obligations, expanded research opportunities, and tax implications worth understanding immediately. Here’s the operational walkthrough.
The narrow scope of what was rescheduled
The order’s reach matters as much as the rescheduling itself. Two specific categories moved from Schedule I to Schedule III: drug products containing marijuana that have been approved by the FDA, and marijuana subject to a state-issued license to manufacture, distribute, and/or dispense for medical purposes only. Everything else — recreational marijuana even in legal states, unlicensed marijuana, bulk material not in an FDA-approved product, synthetically derived THC — remains in Schedule I.
The order was issued under 21 U.S.C. § 811(d)(1), the treaty-compliance pathway, allowing immediate effect without notice-and-comment rulemaking. This is unusual but legally defensible. The Smart Approaches to Marijuana (SAM) coalition has announced plans to challenge the order in court, and the broader rescheduling question — whether all marijuana moves to Schedule III — is the subject of a separate DEA hearing beginning June 29, 2026.
What this changes for two-hat DOs at the operational level
Three changes matter most. First, expedited DEA registration. The order created a fast-track federal registration pathway for entities holding state medical marijuana licenses, with a 60-day application window closing June 22, 2026. Practitioners can also engage in research on marijuana if they are registered with DEA to conduct such research and obtain marijuana from a state licensee with a valid federal registration at time of transfer.
Second, Section 280E tax relief. Section 280E denied ordinary business deductions to businesses trafficking in Schedule I or Schedule II controlled substances. Now that qualifying state medical marijuana is Schedule III, state-licensed operators are no longer subject to 280E’s deduction disallowance. Current guidance suggests this relief applies to the entire 2026 taxable year, with DEA encouraging Treasury to consider retrospective relief for prior tax years.
Third, expanded research opportunities. The order specifically enables clinical research on cannabis products, registered through DEA, with material sourced from state-licensed operators. For DOs interested in contributing to the evidence base for cannabis-based care for veterans — particularly chronic pain, PTSD, sleep continuity, and CUD screening — the research pathway is more accessible than it has been in over fifty years.
VHA Directive 1315 still stands. VA clinicians cannot recommend medical marijuana, register veterans for state programs, or complete state cannabis paperwork. The VA does not pay for cannabis. Cannabis remains prohibited on VA property. None of the April 23 order addresses VA policy on cannabis. The two-hat model — DO operating CCN under one hat, state cannabis evaluation under the other — exists precisely because VA policy has not changed.
Three deadlines DOs need on their calendar
DEA administrative hearing begins on broader rescheduling — whether all marijuana (including recreational) moves to Schedule III. Concludes no later than July 15, 2026.
The compliance implications for two-hat DOs
The two-hat model’s structure — separate records, separate billing, separate consents, separate documentation for CCN care and state cannabis evaluations — remains the foundation of compliant operation. The April 23 order doesn’t change this. What it does change is the federal compliance environment surrounding the state cannabis hat.
If you are a state-licensed medical cannabis evaluator: file the DEA registration application before June 22 if you want priority review. Work with tax counsel on Section 280E implications and potential retrospective relief. Update your facility security and recordkeeping practices to meet Schedule III requirements (these are stricter than the prior treatment of state-licensed operations). Maintain state license compliance — DEA registration automatically suspends if the underlying state license is suspended, revoked, or expires.
The CCN hat operates entirely under federal VA Community Care rules. The DEA rescheduling has no operational impact on your CCN practice — the credentialing, authorization, claim submission, and reauthorization workflows continue exactly as before. The 12-month authorization window for 30 standardized services that took effect in 2026 is the bigger CCN-side change for DOs to track.
What to do if you’re not yet operating in both hats
For DOs who currently practice in only one hat — CCN-only or state-cannabis-only — the April 23 order may shift your calculus on whether to add the second hat. Two-hat operation requires meeting both sets of credentialing requirements, maintaining the legal separation between them, and serving veterans across both lanes.
The CCN side requires VA Community Care credentialing through Optum (Regions 1-3) or TriWest (Regions 4-5), with the upcoming CCN Next Generation contract transition expected mid-to-late 2026. The state cannabis side requires whatever state licensing or registration your state requires for medical cannabis evaluation, plus now the federal DEA registration if you want to operate within the new Schedule III framework.
- If state-licensed for medical cannabis, file DEA registration application before June 22, 2026
- Consult tax counsel on Section 280E implications and potential retrospective relief
- Update facility security, recordkeeping, and reporting to meet Schedule III requirements
- Maintain strict separation between CCN records (VA system) and state cannabis records (private)
- Watch June 29 DEA hearing for broader rescheduling implications
- Track the Veterans Equal Access Act in the FY2026 VA appropriations process
- Prepare CCN credentialing packet for upcoming CCN Next Generation transition
- Review your malpractice carrier's coverage for both hats — confirm coverage continues under Schedule III
- Document your two-hat compliance framework in writing — useful in the event of audit on either side
The April 23 DEA order is the most significant federal cannabis policy change in fifty years, but its scope is narrow and its effect on the two-hat model is mostly indirect. The two-hat structure existed precisely because federal/state legal divergence required it. As the federal/state seam evolves, the structure’s importance may shift — but for now, the operating principles for two-hat DOs are clearer, not blurrier. Stay registered. Stay separated. Stay current on the June 29 hearing and the Equal Access Act.
Federal Register — Schedules of Controlled Substances: Rescheduling of Marijuana (April 28, 2026)
Foley & Lardner — Marijuana: Some Products Reclassified to Schedule III (April 2026)
Gibson Dunn — DEA Downschedules State Medical Marijuana to Schedule III
CannDelta — DEA Reschedules Medical Marijuana: Guide for State Licensees & DEA Registration Instructions